A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

NCT05386758 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Impairment

Interventions

DRUG: Molnupiravir

Sponsor

Merck Sharp & Dohme LLC